Dimerix Limited (AU:DXB) has released an update.
Dimerix Limited has successfully entered its second significant licensing agreement for their Phase 3 drug candidate DMX-200, with potential proceeds up to AU$120.5 million plus tiered royalties. In a robust quarter, the company expanded its ACTION3 Phase 3 clinical study globally, planning around 170 sites, and ended with a strong cash position of AU$22.1 million. The company’s engagement has attracted considerable global partnering interest, particularly after positive interim analysis outcomes in the ACTION3 study.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.
